Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 Trial

Table 5

Predictive value of the prognostic stratification schemes in Table 4 using TROG 96.01 trial data with 5-year prostate cancer-specific mortality (± one standard error) as an endpoint.

Author	Variable	Cutpoints, mortality, number of patients				Cutpoints, Mortality, Number of patients				c-index*
	PSADT	≥6 months				<6 months				0.675
Okotie et al. [8]		8±2%				37±4%
		𝑛=280 (58%)				𝑛=205 (42%)
D’Amico et al. [6]	PSADT	≥12 months				<12 months				0.598
Tollefson et al. [14]		6±2%				26±3%
		𝑛=138 (28%)				𝑛=347 (72%)
	GS	≤7				>7
	TTBF	>3 years		≤3 years		>3 years		≤3 years		0.694
Freedland et al. [10]^†	PSADT	≥9 months	<9 months	≥9 months	<9 months	≥9 months	<9 months	≥9 months	<9 months
		3±2%	13±5%	5±4%	35±4%	0%	0%	29±17%	38±6%
		𝑛=139 (29%)	𝑛=57 (12%)	𝑛=41 (8%)	𝑛=151 (31%)	𝑁=14 (3%)	𝑁=7 (1%)	𝑁=7 (1%)	𝑁=69 (14%)
	GS	≤7				>7				0.654
Zhou et al. [13]	PSADT	≥3 months		<3 months		≥3 months		<3 months
		13±2%		53±8%		21±5%		61±12%
		𝑛=340 (70%)		𝑛=48 (10%)		𝑛=76 (16%)		𝑛=21 (4%)
Stephenson et al. [9]	GS	≤7				>7				0.647
	PSADT	>10 months		≤10 months		>10 months		≤10 months
		4±2%		27±3%		11±8%		34±6%
		𝑛=154 (32%)		𝑛=234 (48%)		𝑛=20 (4%)		𝑛=77 (16%)
Buyyounouski et al. [15]	GS	≤6				>6				0.682
	TTBF	≥1.5 years		<1.5 years		≥1.5 years		<1.5 years
		7±2%		46±9%		14±3%		45±5%
		𝑛=143 (29%)		𝑛=33 (7%)		𝑛=213 (44%)		𝑛=96 (20%)

𝑛: number of TROG 96.01 subjects in study stratum; (𝑋%): percentage of total number of TROG 96.01 subjects with biochemical failure (𝑛=485) in the study; GS: Gleason score; PSADT: PSA doubling time; TTBF: time to biochemical failure.
*Harrell’s concordance index (higher c-index indicates that the model has a better predictive power).
^†Due to subject numbers, subsets with PSADT <3 months and >15 months are not presented in the Freedland study.